Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01042314 | Drug-Drug Interaction Study With Aricept® (Donepezil) | PHASE1 | COMPLETED | 18 | — | — | Jan 1, 2010 | Apr 1, 2010 | Jan 25, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Donepezil and BMS-708163 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Donepezil | DRUG | Tablets, Oral, 5 mg, Once Daily, Days 1-28 |
| BMS-708163 | DRUG | Capsule, Oral, 125 mg, Once Daily, Days 15-28 |
Inclusion Criteria: * Healthy men and postmenopausal women Exclusion Criteria: * Medical History and Concurrent Diseases * Gastrointestinal disease * Gastrointestinal bleeding disorders * History of peptic ulcer disease * History of cholecystectomy * History of seizure disorder * History of asthm...